Immunexpress to Submit Molecular 'Immune Response' Sepsis Assay to FDA in May | GenomeWeb

NEW YORK (GenomeWeb) – Immunexpress, a privately held firm that has for several years been developing molecular assay technology to diagnose sepsis, may finally be close to marketing a clinical test in the US.

Having just wrapped up a key clinical trial of its first sepsis assay in around 200 ICU patients, Immunexpress plans to submit the test in May to the US Food and Drug Administration, and hopes it can gain marketing clearance by the end of this year, Immunexpress President and CEO Roslyn Brandon told GenomeWeb this week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.

Sponsored by
BioFire Diagnostics

This webinar will cover an ongoing study to assess whether a rapid PCR-based gastrointestinal panel can improve health outcomes in the emergency room setting.